Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Melanoma: chemotherapy

S M Lee1, D C Betticher, N Thatcher

  • 1CRC Department of Medical Oncology, Christie Hospital NHS Trust, Manchester.

British Medical Bulletin
|July 1, 1995
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Neoadjuvant treatment does not influence PD-L1 expression in stage III non-small-cell lung cancer: a retrospective analysis of tumor samples from the trials SAKK 16/96, 16/00, 16/01, and 16/14.

ESMO open·2023
Same author

Corrigendum to 'Long-term outcomes of operable stage III NSCLC in the pre-immunotherapy era: results from a pooled analysis of the SAKK 16/96, SAKK 16/00, SAKK 16/01, and SAKK 16/08 trials': [ESMO Open Volume 7, Issue 2, (2022), 100455].

ESMO open·2022
Same author

Long-term outcomes of operable stage III NSCLC in the pre-immunotherapy era: results from a pooled analysis of the SAKK 16/96, SAKK 16/00, SAKK 16/01, and SAKK 16/08 trials.

ESMO open·2022
Same author

A study of temperature control in different designs of emergency drug transport bags.

Anaesthesia·2019
Same author

Predictive biomarkers for response to EGFR-directed monoclonal antibodies for advanced squamous cell lung cancer.

Annals of oncology : official journal of the European Society for Medical Oncology·2018
Same author

Statistical controversies in clinical research: futility analyses in oncology-lessons on potential pitfalls from a randomized controlled trial.

Annals of oncology : official journal of the European Society for Medical Oncology·2017
Same journal

Human health in relation to visible, functional, and accessible green space: a systematic review and narrative synthesis of the 3 + 30 + 300 guideline.

British medical bulletin·2026
Same journal

Muscle herniae in exercise-induced leg pain: diagnostic pitfalls and the 'repair paradox'.

British medical bulletin·2026
Same journal

Scaffolds and platelet concentrates in bone regenerative medicine: applications, mechanisms, and future approaches.

British medical bulletin·2026
Same journal

Back squat and deadlift fatiguing protocols elicit distinct countermovement jump profiles: phase-specific predictors and soreness responses.

British medical bulletin·2026
Same journal

Enhancing bone healing through osteogenic medium components: biological roles, mechanisms, and clinical applications.

British medical bulletin·2026
Same journal

Moral injury in healthcare workers: causes & interventions.

British medical bulletin·2026
See all related articles

Metastatic melanoma survival averages six months, influenced by metastasis location and resectability. Non-visceral spread offers better prognosis than visceral involvement for advanced melanoma patients.

Area of Science:

  • Oncology
  • Dermatology
  • Medical Oncology

Background:

  • Systemic metastasis in melanoma significantly impacts patient prognosis.
  • Median survival for patients with metastatic melanoma is approximately 6 months.
  • Survival rates are contingent upon metastasis characteristics.

Purpose of the Study:

  • To review current chemotherapeutic options for malignant melanoma.
  • To discuss new agents and combination therapies for metastatic melanoma.
  • To evaluate the role of surgery, radiotherapy, and systemic therapy in melanoma treatment.

Main Methods:

  • Review of published literature on melanoma treatment.
  • Analysis of chemotherapeutic strategies including multi-agent therapy and high-dose chemotherapy.

Related Experiment Videos

  • Evaluation of palliative chemotherapy roles.

    • Main Results:

    • Non-visceral metastases (skin, lung) correlate with better survival than visceral metastases (liver, brain).
    • Resectability and number of metastases are critical prognostic factors.
    • Chemotherapy primarily serves a palliative role in metastatic melanoma.

    Conclusions:

    • Treatment requires a multidisciplinary approach involving surgery, radiotherapy, and systemic therapy.
    • Prognosis is highly dependent on the sites and extent of metastasis.
    • Ongoing research into novel chemotherapeutic agents and strategies is crucial for improving outcomes.